§ 5-19.1-36.1. Pharmacists — Drug categories — Prescribing.
(a) In accordance with this chapter and regulations adopted by the department of health, a pharmacist may engage in the independent prescribing of drugs, drug categories, or devices that are critical to the improvement of public health in accordance with such products’ federal Food and Drug Administration-approved labeling:
(1) Drugs for medication assisted treatment (MAT) of opioid use disorder;
(2) Nicotine/tobacco cessation products;
(3) Hyperlipidemia medications;
(4) Inhalers for COPD or asthma;
(5) Insulin and diabetes medications;
(6) Drugs to treat hypertension;
(7) Treatment for positive infectious disease point-of-care testing for influenza, COVID-19, group A strep, and other infections approved by the director;
(8) Such other drugs, drug categories, or devices set forth in the regulations promulgated by the department of health in collaboration with the board of pharmacy. A prescribing pharmacist may order and review any clinical laboratory test necessary to appropriately prescribe and manage drugs and devices in accordance with this section.
(b) The department, in collaboration with the board of pharmacy, shall promulgate regulations, including educational requirements, authorizing a pharmacist to prescribe drugs, drug categories, and devices in accordance with this section.
(c) A pharmacist shall be authorized to charge fees in line with other practitioners for services or submit said fees to insurance for reimbursement in accordance with all state and federal laws governing insurance coverage.
(d) The practice of independent prescribing by pharmacists is voluntary and shall not be mandated by employers or regulatory bodies within this state.
History of Section.
P.L. 2026, ch. 84, art. 12, § 2, effective June 12, 2026.